Earlier today, diversified consumer products supplier McPherson’s Ltd (ASX: MCP) announced its preliminary results for 2016. The company has three divisions which are Health and Beauty, Home Appliances and Household Consumables and sells through well-known brands such as Manicare, Euromaid and Multix.

Although sales revenue fell by 10.5% to $312.6 million, underlying net profit after tax (NPAT) rose 12.7% to $13.5 million and underlying earnings-per-share (EPS) rose 9.7% to 13.6 cents. The market responded well to the news with the stock up 15.8% to $1.10 in early afternoon trading.

The company was able to grow profits in spite of falling sales because it discontinued some lower margin product ranges during the year. For example, it divested its Housewares business which accounted for most of last year’s extra revenue.

The result is more impressive than it first seems given the majority of McPherson’s direct costs are in US dollars which strengthened significantly against the Aussie during the period. The company managed to counteract this effect through price rises and cost reductions.

McPherson’s balance sheet strengthened considerably with net debt down by 35.3% to $49.9 million. $20 million of the $27.3 million drop was due to the divestment of the Housewares joint venture, but also cash conversion was strong given the company paid $3.4 million of dividends.

At current prices McPherson’s has an enterprise value-to-earnings ratio (EV/E) of 12. This compares favourably with GUD Holdings Limited (ASX: GUD) which has an EV/E of 23 and is also a diversified supplier of consumer products. GUD is much larger than McPherson’s and is increasingly focused on automotive products whereas McPherson’s is targeting the health and beauty sector.

Health and Beauty now contributes 48% of McPherson’s total revenue, up from 39% two years ago. Consequently, the company has reduced its dependence on the big supermarkets and is increasingly selling through the more profitable pharmacy channel.

In 2014, McPherson’s started distributing Trilogy branded “natural” skincare products on behalf of Trilogy International Ltd which is listed in New Zealand. Trilogy’s share price is up 397.8% in the last year and its NPAT jumped 108% in 2016 on the back surging sales of its Trilogy range.

Trilogy is the top selling “natural” skincare brand in New Zealand and revenue in Australia rose 45.8% to NZ$10.5 million in 2016 through the distribution agreement with McPherson’s. Trilogy has the potential to be a key earnings driver for McPherson’s in future years given the Australian “natural” skincare segment grew by 38% in the year to 13 December 2015.

At some stage currency rates will stop working against McPherson’s and management appear to be doing a decent job of cutting out the deadwood. Furthermore, focusing on the high growth “natural” skincare industry appears to be a sound strategy and so McPherson’s could be one to watch.

However, whilst the company appears to have turned a corner and the stock is selling cheaply, McPherson's remains a small scale distributor without much of a competitive advantage. In my opinion it is better to invest only in high quality companies even if it means paying a little more. That is exactly how 1 man made 100x his money after the age of 50

Few know, that as Warren Buffett blew out the candles on his 50th birthday cake, he had just 1% of his current fortune. Think about it: At an age when most give up hope, Buffett was just getting started on the remaining 99% of his fortune. Goes to show you that it's never too late for you to potentially get rich. Which is why we've gathered the strategies we learned from Buffett, distilled them down to 11 simple lessons, and put it in an exclusive report for you to claim. Just click here to learn more about this handy investing guide.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Matt Brazier has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.